Spry Tirzepatide Review: Cost, a Misleading FDA Badge & Honest Verdict (2026)

Spry: displays an "FDA Approved" badge even though its compounded GLP-1s are not FDA-approved finished drugs — a potentially misleading claim the ranking's own research flagged directly. Every fact here comes from the company's own published program.

A potentially misleading FDA badge

Worth flagging directly: Spry's site displays an "FDA Approved" badge, but compounded semaglutide and tirzepatide are not FDA-approved finished drugs — only the brand molecules underwent that review. This is a real labeling concern worth understanding before you assume the badge means what it implies.

The warning-letter claim, checked and cleared

An earlier version of this review left an unconfirmed FDA warning-letter claim standing against Spry. That claim is withdrawn, and this section is the correction: there is no FDA warning letter on record for this company. On 7 August 2026 FDA's complete warning-letter index was paged in full — all 3,651 rows — and matched offline on the company column, the column FDA itself files a letter under, for both "Spry" and "becomespry". Neither returns a match; the only "Spry" anywhere in the index is an unrelated e-cigarette company. SkinnyRx's own February 2026 letter came back in that same pass as a positive control, which is what makes the zero a result rather than a search that quietly failed. To be exact about what this establishes: as of 7 August 2026, FDA's own warning-letter database holds no warning letter on file for this company. It is emphatically not a clean bill of health — the "FDA Approved" badge above is a live labeling problem, and it is a separate matter from an enforcement action.

What Spry is

Spry is a weight-loss and anti-aging telehealth platform, pairing compounded semaglutide and tirzepatide with three longevity peptides — BPC-157, NAD+, and sermorelin. It names three co-founders directly: Gabriel Mullins, Sara Yoder, and Tyler Bowman — better-than-average transparency.

What Spry costs

Semaglutide runs $199/month and tirzepatide $299/month, both shown on the homepage without a signup wall; peptides run $249-299/month.

The brand-vs-compounded question

Spry dispenses compounded semaglutide and tirzepatide, despite the FDA-approved badge language. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Spry's real strengths: three named co-founders, pricing shown on the homepage with no signup wall, a broader longevity-peptide menu, no contracts or commitment, and a LegitScript certification with a public verification link. The trade-offs, and the most important one this review flags: the potentially misleading "FDA Approved" badge on a compounded product, the intake is reviewed by a nurse practitioner, not an MD, states served aren't disclosed publicly, and the pharmacy partner isn't named. What is no longer a trade-off is the regulatory claim: no FDA warning letter is on record for this company, checked against FDA's complete index on the company column. As with any GLP-1 program, and especially one whose FDA-related badging is worth questioning, ask directly what the "FDA Approved" claim actually refers to; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Spry's named co-founders and upfront pricing are real positives, and the warning-letter claim this site once left hanging over the company is cleared: no such letter exists in FDA's index. The live problem is a different one — the potentially misleading "FDA Approved" badge on a compounded product is worth questioning directly before you trust it. For a provider that doesn't apply an FDA-related badge to a compounded product, compare it against StackMD or Ondra Health. See our best tirzepatide providers ranking for the full field.